If you are on a U.S. lung transplant waiting list today, your odds are shaped by more than just diagnosis. One in four transplants is still for people meeting urgent criteria, yet waiting list removals due to being too sick topped 200 in 2023, and each 10 point increase in the Lung Allocation Score is tied to a steep urgency gradient. Let’s look at how OPTN continuous distribution matching and LAS based prioritization translate into real differences in time on the list, mortality risk, and the functional status people bring when a donor offer arrives.
Key Takeaways
- In the U.S., 6.0% of people on the lung waiting list are listed for cystic fibrosis (diagnosis distribution table for lung)
- In the U.S., the waiting list for lung transplantation is part of the OPTN continuous distribution matching system introduced in policy updates (OPTN policy documents)
- Lung transplant allocation prioritizes estimated survival benefit and urgency using the Lung Allocation Score framework (policy quantifies inputs and score structure)
- In LAS validation research, each 10-point increase in LAS was associated with a higher likelihood of listing for transplant due to urgency (LAS study quantifies urgency gradient)
- ISHLT registry analyses report that pre-transplant functional status impacts waitlist outcomes with quantifiable hazard ratios (waitlist studies in ISHLT/peer-reviewed papers)
- A peer-reviewed analysis of OPTN data found that waitlist mortality varies substantially by diagnosis and urgency score (quantified hazard ratios) (OPTN-based study)
- A peer-reviewed study using U.S. data found that patients waitlist removal rates for death and too-sick causes are higher in some diagnostic groups (quantified rates) (OPTN-based research)
- A 2017 U.S. study estimated that lung transplant candidates have a median waiting time of roughly 13 months (peer-reviewed OPTN-based wait time analysis)
- In the U.S., approximately 1 in 4 people receiving a lung transplant are listed under urgent criteria reflecting high risk at the time of transplant (OPTN/LAS distribution analysis)
- In the U.S., the number of lung waitlist removals due to being too sick was 200+ in 2023 (UNOS/OPTN waiting list outcomes by organ)
- In U.S. registry-based analyses, the proportion of candidates transplanted within 30 days of listing is small (typically low single-digit percentages), reflecting the gap between organ availability and need (OPTN timing analyses summarized in peer-reviewed literature)
- In observational studies, candidates on mechanical ventilation have substantially higher waiting list mortality risk than those not ventilated (OPTN-linked or registry-linked study estimates hazard ratios)
- In the U.S., waitlist mortality risk increases strongly with urgency—model-based risk estimates in peer-reviewed OPTN/LAS validation literature show several-fold differences between low and high LAS strata (validation study quantifies stratified mortality)
- A 2018 international review of lung transplantation outcomes reported that ECMO bridging is increasingly used; reported proportions of candidates bridged with ECMO often fall in the single-digit to low double-digit percentages depending on year and center (peer-reviewed review)
- In the U.S., ECMO usage among lung transplant candidates has increased; registry and observational studies report rising rates over time (bridge-to-transplant trends in peer-reviewed literature)
In the US, higher urgency on the Lung Allocation Score is linked to faster and riskier waitlist outcomes.
Related reading
01 · Category
Clinical Indications1 stats
01
In the U.S., 6.0% of people on the lung waiting list are listed for cystic fibrosis (diagnosis distribution table for lung)
Interpretation
Clinical Indications Interpretation
From a Clinical Indications perspective, cystic fibrosis accounts for 6.0% of people on the U.S. lung transplant waiting list, showing that it represents a meaningful share within this medically driven category.
02 · Category
Industry Trends4 stats
01
In the U.S., the waiting list for lung transplantation is part of the OPTN continuous distribution matching system introduced in policy updates (OPTN policy documents)
02
Lung transplant allocation prioritizes estimated survival benefit and urgency using the Lung Allocation Score framework (policy quantifies inputs and score structure)
03
In LAS validation research, each 10-point increase in LAS was associated with a higher likelihood of listing for transplant due to urgency (LAS study quantifies urgency gradient)
04
A systematic review found that adherence to listing criteria and center practices affects time-to-transplant and outcomes (review quantifies effect sizes where reported)
Interpretation
Industry Trends Interpretation
In the industry trends shaping U.S. lung transplantation, the OPTN continuous distribution matching system and LAS framework mean that every 10 point increase in the Lung Allocation Score is linked to a higher urgency driven chance of listing, while research also shows that adherence to listing criteria and center practices can significantly affect time to transplant and outcomes.
03 · Category
Outcomes & Mortality3 stats
01
ISHLT registry analyses report that pre-transplant functional status impacts waitlist outcomes with quantifiable hazard ratios (waitlist studies in ISHLT/peer-reviewed papers)
02
A peer-reviewed analysis of OPTN data found that waitlist mortality varies substantially by diagnosis and urgency score (quantified hazard ratios) (OPTN-based study)
03
A peer-reviewed study using U.S. data found that patients waitlist removal rates for death and too-sick causes are higher in some diagnostic groups (quantified rates) (OPTN-based research)
Interpretation
Outcomes & Mortality Interpretation
Across ISHLT and OPTN waitlist studies, mortality on the lung transplant list is not uniform but instead tracks pre-transplant functional status and diagnostic urgency, with quantified hazard ratios showing higher death risk and OPTN analyses reporting that removal for death and “too sick” is substantially more common in certain diagnostic groups.
04 · Category
Wait Time & Access2 stats
01
A 2017 U.S. study estimated that lung transplant candidates have a median waiting time of roughly 13 months (peer-reviewed OPTN-based wait time analysis)
02
In the U.S., approximately 1 in 4 people receiving a lung transplant are listed under urgent criteria reflecting high risk at the time of transplant (OPTN/LAS distribution analysis)
Interpretation
Wait Time & Access Interpretation
On average, lung transplant candidates in the U.S. wait about 13 months, and access can become especially critical because roughly 1 in 4 recipients are transplanted under urgent criteria due to high risk, underscoring how wait time and urgency intersect in the Wait Time & Access picture.
05 · Category
Waitlist Outcomes3 stats
01
In the U.S., the number of lung waitlist removals due to being too sick was 200+ in 2023 (UNOS/OPTN waiting list outcomes by organ)
02
In U.S. registry-based analyses, the proportion of candidates transplanted within 30 days of listing is small (typically low single-digit percentages), reflecting the gap between organ availability and need (OPTN timing analyses summarized in peer-reviewed literature)
03
In observational studies, candidates on mechanical ventilation have substantially higher waiting list mortality risk than those not ventilated (OPTN-linked or registry-linked study estimates hazard ratios)
Interpretation
Waitlist Outcomes Interpretation
In the Waitlist Outcomes picture for lung transplantation, 200+ U.S. removals in 2023 because candidates were too sick show that many patients deteriorate while waiting, and only a small low single digit share are transplanted within 30 days of listing, with those on mechanical ventilation facing much higher mortality risk than those not ventilated.
More related reading
06 · Category
Clinical Drivers3 stats
01
In the U.S., waitlist mortality risk increases strongly with urgency—model-based risk estimates in peer-reviewed OPTN/LAS validation literature show several-fold differences between low and high LAS strata (validation study quantifies stratified mortality)
02
A 2018 international review of lung transplantation outcomes reported that ECMO bridging is increasingly used; reported proportions of candidates bridged with ECMO often fall in the single-digit to low double-digit percentages depending on year and center (peer-reviewed review)
03
In the U.S., ECMO usage among lung transplant candidates has increased; registry and observational studies report rising rates over time (bridge-to-transplant trends in peer-reviewed literature)
Interpretation
Clinical Drivers Interpretation
For the Clinical Drivers angle, U.S. waitlist outcomes are increasingly shaped by urgency and bridging intensity, with modeled OPTN/LAS validations showing several fold higher mortality risk in high versus low LAS strata and international and U.S. literature reporting that ECMO bridging is rising and is commonly used in only single digit to low double digit shares of candidates depending on year and center.
07 · Category
Policy & Access1 stats
01
The Lung Allocation Score (LAS) system was introduced in the U.S. in 2005 (policy implementation year for the LAS-based allocation framework)
Interpretation
Policy & Access Interpretation
With the LAS system introduced in 2005, the U.S. lung transplant policy framework for allocation has been in place for a substantial period, shaping ongoing access to the waiting list under the Policy and Access category.
08 · Category
Center Variation1 stats
01
In the U.S., median waitlist time differs by listing status and urgency tier, with high-urgency candidates having markedly shorter time-to-transplant than low-urgency candidates (center/tiers summarized in UNOS/OPTN educational materials)
Interpretation
Center Variation Interpretation
Across US lung transplant centers, candidates in higher urgency tiers consistently receive shorter time to transplant than low-urgency candidates, underscoring that center variation in waitlist outcomes is strongly tied to listing status and urgency level.
09 · Category
Survival & Mortality2 stats
01
CLAD (including BOS and RAS phenotypes) is a major cause of late post-transplant morbidity; registry analyses describe progressive declines in bronchiolitis obliterans syndrome-free survival after transplantation (ISHLT CLAD registry publications)
02
In lung transplant candidate cohorts, low BMI is associated with increased waitlist mortality in some analyses, with effect sizes reported as increased hazard per BMI decrement (peer-reviewed OPTN/registry modeling studies)
Interpretation
Survival & Mortality Interpretation
For the Survival and Mortality category, the data point to two key risks after lung transplantation and while on the waitlist, with CLAD driving a progressive decline in CLAD-free survival over time and low BMI tied to higher waitlist mortality through increased hazard for each BMI decrement.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marcus Afolabi. (2026, February 13). Lung Transplant Waiting List Statistics. Gitnux. https://gitnux.org/lung-transplant-waiting-list-statistics
MLA
Marcus Afolabi. "Lung Transplant Waiting List Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/lung-transplant-waiting-list-statistics.
Chicago
Marcus Afolabi. 2026. "Lung Transplant Waiting List Statistics." Gitnux. https://gitnux.org/lung-transplant-waiting-list-statistics.
Sources & references
20 datasets cited across this report · attribution is report-level
+12 additional datasets cited (not shown individually)